Significant Post-Chemotherapy Decrease of Ovarian Reserve in Iranian Women With Breast Cancer

  • Bita Eslami ORCID Breast DiseasesResearch Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran
  • Amirmohsen Jalaeefar ORCID Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
  • Ashraf Moini ORCID Breast Diseases Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran. AND Department of Gynecology and Obstetrics, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
  • Ramesh Omranipour Breast Diseases Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran. AND Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Maryam Haghighi ORCID Breast Oncology Clinic, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  • Sadaf Alipour ORCID Mail Breast Diseases Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran. AND Department of Surgery, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Keywords:
Breast cancer, Anti-mullerian hormone, Ovarian reserve, Chemotherapy

Abstract

Fertility preservation counseling has a high priority in young breast cancer (BC) patients. Cytotoxic chemicals used for chemotherapy in these patients increased the risk of premature ovarian failure. This study evaluated the anti-mullerian hormone (AMH) level at the time of diagnosis and within a month after the end of chemotherapy, while predicting the time of the return of ovarian function in BC cases (n=46) younger than 46 years for the first time in Iran. Cases were selected from those attending the breast oncology clinic of the two hospitals with a newly diagnosed in situ or invasive BC. The present study results showed AMH levels were significantly decreased in almost all women within a month after chemotherapy. It seems that the need for fertility preservation depends on patient age and baseline AMH level, but counseling should be offered by the clinician in young breast cancer patients.

References

1. Cook CL, Siow Y, Taylor S, Fallat ME. Serum müllerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 2000;73:859-61. doi:10.1016/s0015-0282(01)02944-2
2. Montazeri A, Vahdaninia M, Harirchi I, Harirchi AM, Sajadian A, Khaleghi F, et al. Breast cancer in Iran: need for greater women awareness of warning signs and effective screening methods. Asia Pac Fam Med 2008;7:6. doi: 10.1186/1447-056X-7-6
3. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31. doi:10.1200/JCO.2006.06.5888
4. Ruddy KJ, O’Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, et al. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Ttreat 2014;144:591-7. doi: 10.1007/s10549-014-2891-0
5. Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 2008;26:286-95. doi:10.1080/07357900701829777
6. Su HC, Haunschild C, Chung K, Komrokian S, Boles S, Sammel MD, et al. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer 2014;120:3691-8. doi:10.1002/cncr.28942
7. Yu B, Douglas N, Ferin MJ, Nakhuda GS, Crew K, Lobo RA, et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010;116:2099-105. doi:10.1002/cncr.25037
8. Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 2014;19:68. doi: 10.1634/theoncologist.2013-0145
9. Son K-A, Lee D-Y, Choi D. Association of BRCA mutations and anti-Müllerian hormone level in young breast cancer patients. Front Endocrinol 2019;10:235. doi:10.3389/fendo.2019.00235
10. Bai F, Lu Y, Wu K, Chen Q, Ding L, Ge M, et al. Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients: a systematic review and meta-analysis. Breast Care 2017;12:46-50. doi: 10.1159/000454983
Published
2020-11-10
How to Cite
1.
Eslami B, Jalaeefar A, Moini A, Omranipour R, Haghighi M, Alipour S. Significant Post-Chemotherapy Decrease of Ovarian Reserve in Iranian Women With Breast Cancer. Acta Med Iran. 58(8):400-403.
QRcode
Section
Articles